I’m proposing that the unexpected lifespan extension seen in SIRT3-deficient mice under caloric restriction (CR) stems from what I’m calling the Acetyl-CoA Flux-Lock. In this model, SIRT3’s role in mitochondrial deacetylation acts as a metabolic brake, preventing the necessary shift toward lipid-derived signaling during nutrient scarcity. I believe that in long-lived mammals, evolutionary lysine-to-arginine substitutions in enzymes like HMGCS2 and AceCS2 lock these proteins into a constitutive active state. This bypasses the need for SIRT3-mediated toggling and reduces the cell's reliance on NAD+ turnover.

While SIRT3 is typically labeled an activator (SIRT3-mediated HMGCS2 activation), its function depends on the mitochondrial NAD+/NADH ratio. During CR, cells rely on metabolic plasticity. If SIRT3 stays hyperactive, it locks enzymes into a rigid, standard oxidative mode.

My reasoning breaks down into three points:

1. The NAD+ Tax: High SIRT3 activity consumes NAD+, which is already scarce during caloric stress. By hard-wiring longevity enzymes through R/Q substitutions (mammalian longevity acetylome), the cell avoids this NAD+ tax and skips the SIRT3-dependent checkpoint.
2. Competitive Acetylation: SIRT3 deficiency during CR might actually prevent metabolic entrapment. Without SIRT3, the mitochondrial proteome becomes hyperacetylated in a way that, surprisingly, allows the cell to shift toward slower, more efficient catabolic pathways that remain blocked when SIRT3 is forcing rapid oxidative turnover.
3. Compartmental Desynchronization: If cytoplasmic SIRT1 promotes lipid mobilization while mitochondrial SIRT3 suppresses ketogenic pathways due to low substrates, the cell hits a metabolic bottleneck (Ongoing Thread: CAD Hypothesis). SIRT3 deficiency resolves this by letting the mitochondria synchronize with the cytosol.

To test the Flux-Lock model, we should use CRISPR to knock in 'deacetylation-mimicker' (Lys-to-Arg) mutations into primary mouse hepatocytes. We’ll compare the metabolic flexibility of wild-type, SIRT3-/-, and 'Lock-in' mutant mice—those with fixed R-substitutions at SIRT3-targeted sites—across various caloric loads.

If the 'Lock-in' mutants show the same metabolic profiles as wild-type mice regardless of SIRT3 status, it suggests that R-substitution is the superior, evolutionarily favored way to avoid the SIRT3-imposed brake. If these mutants keep ATP production high even when NAD+ is low, it proves that reducing the acetylome burden is functionally distinct from—and better than—relying on high deacetylase activity.

This framework suggests we should stop trying to "boost" SIRT3. Instead, we should look for pharmacological agents that mimic the structural conformations of permanent deacetylation, essentially re-engineering the aging proteome to match that of long-lived species.